CMV Clinical Trial
Official title:
Incidence, Natural History and Outcome of Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer Therapy
Cytomegalovirus (CMV) is the most common member of the herpes viruses to infect humans. Its double-stranded linear DNA duplex contains 165 genes that encode viral proteins that mimic and interact with human cellular proteins and are related to its virulence and latency. CMV primary infection is usually acquired in the adolescence and follows a benign course; however it might reactivate in patients with immune suppression leading to a high mortality and morbidity in this group of patients. There is growing evidence that critically ill immunocompetent patients can develop CMV disease [Limaye et al. JAMA. 2008;300(4):413; Ziemann et al. Crit Care Med. 2008;36(12):3145]. However, results of the incidence of CMV disease in critically ill patients is unpredictable due to the wide range of these results, from a 0% to 98% [Al-Omari et al. Ann. Intensive Care (2016) 6:110]. This inconsistency could be explained by many factors such as (i) variation in the definition of CMV disease (old studies consider seropositivity as evidence of disease, while others use newer technologies like PCR and/or antigen detection), (ii) variation in inclusion criteria (some studies include only seropositive patients therefore assessing reactivation rate of CMV, others also include seronegative patients thus evaluating also new infections) or (iii) variation in studied populations (e.g. septic, surgical, burn or postcardiac surgery patients or patients under mechanical ventilation).
Evidence in the literature has demonstrated how different factors have been associated with
CMV disease; however, the effect of new anticancer therapies (personalized chemotherapies,
biological and immunological treatments, extreme surgery, etc.) on CMV disease is unknown.
The investigators believe that studying this subgroup of patients should be one of the
primary issues as the number of patients with these characteristics will increase
significantly in the near future.
Likewise, it is important to point out that in the real world diagnosing CMV disease is a
real challenge for the intensive care physician (due to subclinical or not specific clinical
presentations, confusion factors, low clinical suspicions, etc.) thus its diagnosis and
eventual treatment could be improved. These undesired diagnostic and therapeutic flaws
provide a unique opportunity to (i) describe the natural evolution of the disease, (ii)
address the effect of the disease in the outcome of the patients and (iii) estimate the
potential number of patients that could benefit from a new management.
HM Hospitales (https://www.hmhospitales.com/) is a Spanish private group made up of five
tertiary university hospitals in Madrid (HM Madrid, HM Torrelodones, HM Sanchinarro, HM
Puerta del Sur y HM Monteprincipe). In addition, the group has a specialized center focused
in cancer ("Clara Campal" oncologic center https://www.hmciocc.com/ ) with a phase I Unit
(STAR-CIOCC
http://startmadrid.com/index.php/en/2014-10-02-23-29-01/madrid-locations/2014-10-10-00-46-42)
, five medical-surgical ICUs (one in each hospital) that assist 1200 patients/year (35% with
cancer) and a surgical department specialized in robotic and laparoscopic procedures.
To define the incidence of CMV reactivation and disease is of paramount importance as several
studies have suggested an association between CMV disease and an increased mortality rate,
prolonged mechanical ventilation as well as length of ICU and hospital stay. Furthermore, CMV
disease increases the risk of acquiring a nosocomial infection that could also have an effect
on the outcome of the patients [Ziemann et al. Crit Care Med. 2008;36(12):3145; Sinclair. J
Clin Virol. 2008;41(3):180]. Likewise, as several anti-CMV treatments are (valacyclovir,
valanciclovir, ganciclovir, foscarnet or cidofovir), or will be shortly (letermovir),
available the increased morbidity and mortality associated to this infection in critically
ill patients could be improved dramatically.
This research proposal is seeking to answer four questions in a general ICU cohort of
patients and in the subgroup of critically ill patients receiving anti-cancer therapy:
1. Which is the incidence of CMV infection and disease?
2. What is the natural evolution of CMV infections that do not receive anti-CMV treatment?
3. What is the impact of anti-CMV treatment in the patient´s outcome (mortality, days under
mechanical ventilation and days at ICU)?
4. What are the risk and protective factors for developing CMV infection after ICU
admission?
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04101136 -
Effect of Atorvastatin on Subclinical Atherosclerosis
|
N/A | |
Recruiting |
NCT06001320 -
De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip
|
Early Phase 1 | |
Completed |
NCT01923766 -
Cytotoxic T Cells to Prevent Virus Infections
|
Phase 1 | |
Not yet recruiting |
NCT05969743 -
Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease
|
Phase 2 | |
Recruiting |
NCT01011712 -
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
|
||
Recruiting |
NCT06034925 -
Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT04840199 -
A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.
|
Phase 2 | |
Terminated |
NCT03502161 -
Clinical Evaluation of the QuantiFERON CMV Assay
|
||
Not yet recruiting |
NCT06211543 -
Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers
|
||
Recruiting |
NCT04056533 -
Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy
|
Phase 2 | |
Active, not recruiting |
NCT03924219 -
CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
|
||
Not yet recruiting |
NCT06453460 -
Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla
|
Phase 2 | |
Completed |
NCT02694484 -
Search Cytomegalovirus in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant
|
N/A | |
Recruiting |
NCT06011486 -
Expansion of Virus-Specific Lymphocytes for Cell Therapy
|
Phase 1 | |
Recruiting |
NCT04017962 -
A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection
|
Phase 2 | |
Terminated |
NCT03570411 -
Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant
|
||
Enrolling by invitation |
NCT04392297 -
Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals
|
||
Completed |
NCT00872703 -
Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection?
|
N/A | |
Active, not recruiting |
NCT01945814 -
Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)
|
Phase 1 | |
Recruiting |
NCT05041426 -
Letermovir for CMV Prevention After Lung Transplantation
|
Phase 2 |